⌕
Summit Therapeutics · SMMT · Nasdaq
Tenet 27 · Weak
Compare
$14.15−6.14%At closeTenet 27 · Weak
$14.15−0.93 (−6.14%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Summit Therapeutics (SMMT) Stock

Summit Therapeutics (SMMT) closed at $14.15 on Nov 13, 2026; its Tenet Score is 27 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$14.15
Nov 13, 2026
Market cap
$9.9B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
12.07 – 29.23
low → high
Tenet Score
27/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Summit Therapeutics Inc scores 27/100. Weak. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 27 is built from 3 of 4 pillars, from 30% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
27/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
8
Quality
4
Health
70
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthBGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
no P/E on file
P/B
—
no P/B on file
P/S
—
no P/S on file
ROE
—
no ROE for this year, and Tenet does not compute one yet
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
—
no current ratio on file
Net debt / EBITDA
—
no leverage ratio on file
EPS CAGR 5y
—
needs five years of positive earnings
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Summit Therapeutics Inc

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI).…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 79 US ETFs · top wrappers by weightSee all ETFs holding SMMT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Summit Therapeutics in?

Summit Therapeutics is in the Healthcare sector and the Drugs industry.

What is Summit Therapeutics' Tenet Score?

Summit Therapeutics' Tenet Score is 27 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.